BioKangtai(SZ:300601)2022-11-21 05:28Group 1: Vaccine Development Progress - The 13-valent pneumococcal polysaccharide conjugate vaccine is the world's first dual-carrier vaccine, which received drug registration certification in September 2021 and has been approved for market entry in several provinces [2][3] - The freeze-dried rabies vaccine (human diploid cells) has received acceptance for production registration from the National Medical Products Administration, with ongoing evaluations and trials [3][4] - The inactivated COVID-19 vaccine has been granted emergency use approval in May 2021 and is currently undergoing Phase III clinical trials overseas [3][4] Group 2: Future Product Pipeline - Expected upcoming products include the freeze-dried rabies vaccine, freeze-dried varicella vaccine, and Sabin strain inactivated poliovirus vaccine, with plans for multi-valent vaccines such as the 20-valent pneumococcal polysaccharide conjugate vaccine [4][5] - The company is actively monitoring strain mutations and will disclose new developments as per regulations [4][5] Group 3: International Expansion Strategy - The company has implemented a "bring in" and "go out" strategy, enhancing R&D capabilities through international collaborations and technology imports [5] - The adenovirus COVID-19 vaccine has received emergency use authorization in Indonesia, facilitating future export opportunities [5] Group 4: Sales and Marketing Strategy - The sales team currently consists of over 1,000 members, with plans for expansion as new products are launched [5] - The company aims to enhance its marketing strategies by improving product medical manuals and strengthening academic training for the sales team [5]